Vitestro Funding, Investors & Competitors

Vitestro has raised $104M across 3 funding rounds, most recently a $70M Series B in March 2026.

Last Vitestro funding round

$70M

Series B · Mar 2026

Cumulative funding Vitestro raised

$104M

across 3 funding rounds

Key investors in Vitestro

  • Sonder Capital
  • European Innovation Council
  • NYBC Ventures
  • InterVest Co.
  • Mayo Clinic
  • Invest-NL
  • PGGM Investments
  • LabCorp Venture Fund

Vitestro Overview

About Vitestro

Vitestro is an Eindhoven-headquartered medtech company pioneering autonomous robotic phlebotomy devices that perform blood draws without needles visible to patients. The Vitestro One system uses ultrasound-guided lancets to collect up to 12 milliliters of blood in seconds, reducing pain and vein misses by 80 percent. Deployed in over 20 hospitals across Europe and the U.S., including Erasmus MC, the technology integrates with EHR systems for seamless lab workflows. Founded in 2019 by Eindhoven University alumni, Vitestro raised €25 million in Series A funding.


Founded

2017

HQ

NetherlandsUtrecht

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Vitestro Funding History

Vitestro has raised a total of $104M across 3 funding rounds.

Vitestro's first fundraising round was a $13M Series A in March 2023. The most recent completed round was a $70M Series B in March 2026.

Vitestro funding rounds

Vitestro funding rounds
DateStageInvestorsRaisedDeal Summary
Mar 2026Series BEuropean Innovation Council; Sonder Capital; MGFO; Puma Venture Capital; ROM Utrecht Region; PGGM Investments; InterVest Co.; LabCorp Venture Fund; NYBC Ventures; Sutter Health; Mayo Clinic; Intervest$70M-
Apr 2024Series ANYBC Ventures (lead); Sonder Capital (lead); European Innovation Council; Invest-NL$21MVitestro is a pioneering autonomous blood drawing company based in Utrecht, The Netherlands, developing Aletta, the world's first fully autonomous robotic device for diagnostic blood collection. The device handles the complete blood draw process from tourniquet application to bandaging using artificial intelligence, near-infrared imaging, ultrasound, and Doppler imaging technology to identify veins accurately and address cases where traditional phlebotomy methods fail. On April 30, 2024, Vitestro announced the close of a $22 million (€20 million) Series B funding round co-led by return investor Sonder Capital and new investor NYBC Ventures, with participation from Invest-NL, the European Innovation Council Fund, and existing private investors. The round was oversubscribed and brought Vitestro's total funding raised to $50 million (€46 million) from both equity investments and grant funding. The capital was designated to accelerate Vitestro's commercialization efforts in Europe and facilitate organizational expansion into the U.S. market, with the company aiming to obtain CE approval for its device by the end of 2024 and commence deployment simultaneously. Vitestro was also leading the A.D.O.P.T. trial, described as the world's largest evaluation of autonomous blood drawing devices, with early feedback from hospitals, staff, and patients reported as overwhelmingly positive. Dr. Fred Moll, co-founder of Intuitive Surgical and managing partner at Sonder Capital, highlighted the market opportunity, noting that diagnostic blood collection represents the highest-volume invasive medical procedure globally with billions of procedures performed annually, while laboratories face staffing challenges and capacity constraints.
Mar 2023Series ASonder Capital (lead); Addington Investment Group$13MVitestro raised an undisclosed amount in a Series A round on March 21, 2023, with participation from Sonder Capital and Addington Investment Group. The Dutch medtech company develops the Aletta Autonomous Robotic Phlebotomy Device for automated blood collection using AI, near-infrared, ultrasound, and Doppler imaging. This round preceded a June 2023 incubator/accelerator and a $22M Series A-II on April 30, 2024, involving Sonder Capital, NYBC Ventures, European Innovation Council, and Invest-NL. Vitestro later secured a $70M oversubscribed Series B in March 2026 from investors including Labcorp Venture Fund, Mayo Clinic, Sutter Health, and existing backers like Sonder Capital and NYBC Ventures to advance FDA clearance, manufacturing scale-up, and global commercialization starting in Europe.

Who has invested in Vitestro?

14 investors have backed Vitestro across its funding rounds, including Sonder Capital, European Innovation Council, NYBC Ventures, InterVest Co., Mayo Clinic and Invest-NL.

Lead investors include NYBC Ventures and Sonder Capital.


Vitestro Investors

Investors in Vitestro by funding rounds participated
InvestorHQRoundsRoleFirst check
Sonder CapitalUnited StatesSan Francisco, CA3LeadMar 2023
European Innovation CouncilBelgiumBrussels2ParticipantApr 2024
NYBC VenturesUnited StatesBoston, MA2LeadApr 2024
MGFOBahamasNassau1ParticipantMar 2026
Puma Venture CapitalUnited StatesSan Diego, CA1ParticipantMar 2026
ROM Utrecht RegionNetherlandsUtrecht1ParticipantMar 2026
PGGM InvestmentsNetherlandsUtrecht1ParticipantMar 2026
InterVest Co.South KoreaSeoul1ParticipantMar 2026
LabCorp Venture FundUnited StatesUnited States1ParticipantMar 2026
Invest-NLNetherlandsAmsterdam1ParticipantApr 2024
Addington Investment GroupNetherlandsRotterdam1ParticipantMar 2023
Sutter HealthUnited StatesSacramento, CA1ParticipantMar 2026

This data is available for Pro users. Sign up to see all 14 Vitestro investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Vitestro Competitors

Vitestro competitors include listed companies like Siemens, Johnson & Johnson, Roche and Thermo Fisher Scientific, and private ones like Biosplice Therapeutics and Neuralink.

Public and private companies comparable to Vitestro
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
SiemensGermanyGermanyPublicly listed$91B$15B$234B2.9x
Johnson & JohnsonUnited StatesUnited StatesPublicly listed$94B$40B$651B6.8x
RocheSwitzerlandSwitzerlandPublicly listed$77B$26B$351B4.9x
Thermo Fisher ScientificUnited StatesUnited StatesPublicly listed$45B$11B$243B6.0x
Biosplice TherapeuticsUnited StatesSan Diego, CAPrivate--$12B-
NeuralinkUnited StatesUnited StatesPrivate--$9B-

Vitestro Public Comps

Vitestro is still privately-owned, but its public comps include Samsung, Johnson & Johnson, Roche, Thermo Fisher Scientific, Siemens, Schneider Electric, Abbott, ABB, Hitachi and Danaher.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Samsung$243B$67B4.4x2.4x15.8x4.4x
Johnson & Johnson$94B$40B7.2x6.8x17.0x18.3x
Roche$77B$26B5.0x4.9x14.6x12.4x
Thermo Fisher Scientific$45B$11B6.3x6.0x26.8x23.6x
Siemens$91B$15B3.0x2.9x18.1x15.7x
Schneider Electric$46B$9.5B4.3x3.9x21.0x18.4x
Abbott$44B$12B4.6x4.2x17.4x15.8x
ABB$33B$6.9B5.4x4.9x25.9x22.6x

This data is available for Pro users. Sign up to see all Vitestro competitors and their valuation data.

Start Free Trial

Common questions about Vitestro

When was Vitestro founded?Vitestro was founded in 2017.
Where is Vitestro headquartered?Vitestro is headquartered in Utrecht, Netherlands.
Is Vitestro publicly listed?No, Vitestro is a private, VC-backed company.
How much funding has Vitestro raised?Vitestro has raised $104M across 3 funding rounds.
What was Vitestro's last funding round?Vitestro's last funding round was a $70M Series B in March 2026.
Who are Vitestro's investors?Vitestro's investors include Sonder Capital, European Innovation Council, NYBC Ventures, MGFO, Puma Venture Capital, ROM Utrecht Region, PGGM Investments, InterVest Co., LabCorp Venture Fund, Invest-NL and 4 others.
Which companies are comparable to Vitestro?Companies comparable to Vitestro include Siemens, Johnson & Johnson, Roche, Thermo Fisher Scientific, Biosplice Therapeutics and Neuralink.

See companies similar to Vitestro

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial